• SPX
  • $5,859.85
  • 0.77 %
  • $44.82
  • DJI
  • $43,065.22
  • 0.47 %
  • $201.36
  • N225
  • $40,232.40
  • 1.58 %
  • $626.67
  • FTSE
  • $8,292.66
  • 0.47 %
  • $39.01
  • IXIC
  • $18,502.69
  • 0.87 %
  • $159.75
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News & Analysis

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.81

$0.37

(8.33%)

Day's range
$4.77
Day's range
$5.3
50-day range
$4.35
Day's range
$5.53
  • Country: US
  • ISIN: US9216591084
52 wk range
$3.3
Day's range
$6.75
  • CEO: Dr. Mihael H. Polymeropoulos M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.98
  • Piotroski Score 2.00
  • Grade Hold
  • Symbol (VNDA)
  • Company Vanda Pharmaceuticals Inc.
  • Price $4.81
  • Changes Percentage (8.33%)
  • Change $0.37
  • Day Low $4.77
  • Day High $5.30
  • Year High $6.75

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $11.00
  • High Stock Price Target $11.00
  • Low Stock Price Target $11.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.09
  • Trailing P/E Ratio -68
  • Forward P/E Ratio -68
  • P/E Growth -68
  • Net Income $2.51 M

Income Statement

Quarterly

Annual

Latest News of VNDA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.